PubMed Health⌕ Search

Biomedical subjects

M Kanzler

Publications and source records attributed to M Kanzler.

At least 19 recordsLinked to original sources
PubMed1987

Effects of electrode placement on the efficacy of titrated, low-dose ECT.

This double-blind, random-assignment study contrasted the relative efficacy of bilateral and unilateral right ECT with a low-dose titration procedure. In 52 patients with primary major depressive disorder, bilateral ECT was markedly superior in short-term symptom reduction to unilateral right ECT. The two conditions did not differ in the duration of generalized seizures or in the number of treatments administered to achieve clinical response. The findings challenge the claim that the elicitation of generalized seizure is, in and of itself, sufficient for the antidepressant properties of ECT. Rather, a dose in excess of seizure threshold may contribute to the efficacy of ECT, particularly with a unilateral right electrode placement.

Clinical Trials as Topic↗
PubMed1983

Low nicotine cigarettes: cigarette consumption and breath carbon monoxide after one year.

Subjects who took part in a 12-wk study of switching behavior were observed during the subsequent year. Data were obtained for 96 smokers every 3 mo. A sample of smokers who, at 12 wk, had switched to a brand delivering less than half the nicotine of their baseline brand were offered continued monetary incentives to participate for an additional 6 mo (maintenance study). In the maintenance study, subjects continued to smoke low-nicotine cigarettes during the 6-mo period in which money and contact reinforcement were continued; maintenance control subjects increased their tar and nicotine exposure significantly. In the follow-up study of those who had not changed by more than 50%, the original control group, nonswitchers, and moderate switchers did not significantly change their nicotine exposure from what it had been at the end of the initial 12-wk study. Carbon monoxide (CO) in breath showed remarkably little change across the year despite substantial changes in tar and nicotine exposure. To the extent that CO is involved in smoking-related disorders, switchers derived little if any benefit from switching to low-nicotine brands.

Adult↗
PubMed1980

Abuse potential of loperamide.

Effects of the currently marketed form of loperamide (Imodium capsules) that might relate to abuse potential were examined. Study I was a double-blind "dose run-up" in adult male subjects with a history of illicit drug use but no history of opioid addiction. Subjective responses to doses of loperamide ranging from 12 to 60 mg were compared with responses to 120 mg codeine sulfate (96 mg base) and to placebo. Based on study I, loperamide (60 mg) was used in study II and its effects were compared with those of codeine (96 mg base) and placebo in an exaddict subject group. Study II subjects had had extensive opioid experience but were not actively addicted at the time of this double-blind, inpatient study. In study II, as in study I, unlike loperamide and placebo, codeine induced pupillary constriction. Loperamide (60 mg) induced a detectable subjective effect in somewhat over half the subjects, was "liked" little or not at all, and was identified as "dope" at a frequency less than that for a threshold dose of oral codeine. It was concluded that in its present form, i.e., capsules containing loperamide mixed with magnesium stearate, loperamide poses little threat of potential abuse.

Adult↗